Results 51 to 60 of about 5,867,860 (378)

CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism

open access: yesmAbs, 2020
Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic activity.
Johannes Nelke   +4 more
doaj   +1 more source

COMMON INDIVIDUAL ANTIGENIC DETERMINANTS IN FIVE OF EIGHT BALB/c IGA MYELOMA PROTEINS THAT BIND PHOSPHORYL CHOLINE

open access: yesJournal of Experimental Medicine, 1970
Eight IgA myeloma proteins derived from independently induced plasma-cytomas in genetically similar inbred BALB/c mice are functionally related by their binding of phosphoryl choline-containing antigens (Pneumococcus C polysaccharide or Lactobacillus ...
M. Potter, R. Lieberman
semanticscholar   +1 more source

Elotuzumab as a novel anti-myeloma immunotherapy

open access: yesHuman Vaccines & Immunotherapeutics, 2017
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches.
Sabarinath Venniyil Radhakrishnan   +5 more
doaj   +1 more source

Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. [PDF]

open access: yesPLoS ONE, 2012
Multiple myeloma is a haematological malignancy characterized by the clonal proliferation of plasma cells. It has been proposed that targeting cancer cell metabolism would provide a new selective anticancer therapeutic strategy.
José Manuel Tirado-Vélez   +4 more
doaj   +1 more source

Dissecting apoptosis the omics way [PDF]

open access: yes, 2013
A combined analysis of transcription, translation and protein degradation reveals the global effects of an anticancer drug on tumour ...
Agard   +8 more
core   +2 more sources

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

open access: yesHaematologica, 2014
A multistep model has been proposed of disease progression starting in monoclonal gammopathy of undetermined significance continuing through multiple myeloma, sometimes with an intermediate entity called smoldering myeloma, and ending in extramedullary ...
Lucía López-Corral   +15 more
doaj   +1 more source

Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14

open access: yesCellular Physiology and Biochemistry, 2018
Background/Aims: The purpose of our experiments was to investigate the targeting relationship of linc00515, miR-140-5p and ATG14 and to explore the roles of linc00515, miR-140-5p and ATG14 in autophagy and chemoresistance of melphalan-resistant multiple ...
Daifeng Lu   +4 more
doaj   +1 more source

Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit?

open access: yesFrontiers in Oncology, 2023
Matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) play a vital role in the pathogenesis of multiple myeloma (MM), especially for tumor invasion and osteolytic osteopathy.
Yan-Ying Li   +7 more
doaj   +1 more source

SPECIFICITY OF RECOMBINATION OF H AND L CHAINS FROM HUMAN γG-MYELOMA PROTEINS

open access: yesJournal of Experimental Medicine, 1965
Dissociated H and L chains of human γG-myeloma proteins were recombined by removal of conditions interrupting non-covalent interactions. In the process of recombination 7S molecules were formed.
H. Grey, M. Mannik
semanticscholar   +1 more source

Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]

open access: yes, 2014
Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy